Runs a free AI Fellows program connecting founders to former Fortune 100 health CEOs, tailored go-to-market training, enduring partner mentorship, and network of payers, providers, employers, and life-science companies. With a clear focus on healthcare innovation, the firm brings both capital and domain expertise.
1CC.VC, a digital asset trading framework that delivers users with access to a expansive range of digital assets, encompassing cryptocurrencies, stablecoins, and tokens, continues to make its mark. The framework is built to be user-friendly and capabilities a variety of features, such as charting instruments, real-time trading, margin trading, and sophisticated order types. Furthermore, 1CC.VC also capabilities a variety of educational assets to help users learn more about digital assets and trading. The platform is built on top of a protected and dependable infrastructure, and its solutions are available in both English and Chinese.
Venture studio and fund that co‑incubates with LifePoint executives, giving startup ventures direct access to a $50B+ health system for pilot deployment, real‑world validation, and underserved population focus. Through targeted capital deployment, the fund plays an active role in the startup ecosystem.
30n operates as a venture fund geared toward investing in early-phase emerging ventures with a mission to create an equitable and sustainable future. They invest in a suite of industries, including technology, media, health care, and finance, and are driven to creating long-term value for their portfolio ventures. Their portfolio includes companies working on aI-powered technology, health tech, software, hardware, and more. Furthermore, fund also delivers resources to their portfolio ventures such as mentorship, network access, and strategic advice. 30n maintains a presence in San Francisco, New York, and London.
Early-phase partner for founders building iconic, industry-transforming companies, demonstrated by two new funds totaling $347M. With a disciplined investment approach, the team drives value for both founders and investors.
Acts as a VC and venture studio—co-founds emerging ventures with 25–30% of capital, assembles top‑1% specialists, and builds national‑capability defense, industrials, and bio‑infrastructure companies with corporate partners. The firm continues to build its presence across the venture capital landscape.
Women-led VC systematically backs clinically rigorous, behaviorally grounded wellbeing nascent-stage companies tackling stigmatized areas—alcohol use disorder, menopause, mental health—using stigma as an investing edge and insisting on consumer-grade UX. With a disciplined investment approach, the team drives value for both founders and investors.